SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing intense investor scrutiny following its recent earnings report, with the stock experiencing significant after-hours volatility despite an earnings beat. Community sentiment is largely divided, balancing the long-term strategic potential of the proposed Warner Bros. Discovery acquisition and its associated intellectual property against concerns over a pause in share buybacks and a cautious outlook. Discussions are heavily focused on whether current price levels represent a significant buying opportunity or signal further downside amidst an evolving competitive streaming environment.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is experiencing a major surge as extreme cold weather forecasts, including polar vortex threats, fuel expectations for significantly increased natural gas demand across the US. The community is buzzing with predictions of a massive short squeeze, though some caution about the inherent volatility and historical patterns of natural gas's rapid movements.

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. It focuses on the exploration, development, mining, and processing of rare earth deposits. The company was founded by Nicholas Anthony Curtis on May 23, 1983 and is headquartered in Perth, Australia.

Lynas Rare Earths Limited

Lynas Rare Earths is gaining significant attention following its strategic partnership with Noveon Magnetics to establish a domestic U.S. supply chain for rare earth permanent magnets, a move strongly supported by broader geopolitical initiatives to reduce reliance on foreign supply. The community is keenly anticipating the upcoming quarterly results for further insights, viewing Lynas as a crucial player positioned to benefit from the tightening global rare earths market amidst increasing demand and strategic government focus on critical minerals.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial data for its oral eczema drug, soquelitinib, which showed significant skin improvement and a favorable safety profile, even in patients resistant to other therapies. The community is buzzing about its potential as a game-changer in a large market, leading to speculation about future partnerships or a buyout, though some are anticipating a potential share offering following the rapid appreciation.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies Global (AVR) is trending following news of a strategic private placement with Medtronic and the enrollment of the first patients in its global pivotal PARADIGM trial for the DurAVR heart valve. The community is actively discussing the validation from Medtronic's investment and the significant milestone of advancing its core product, with many believing the stock remains undervalued despite recent share offerings.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst significant downward pressure, pushing its RSI to historically oversold levels reminiscent of major market downturns and sparking intense debate among traders. While many in the community point to technical breakdowns and broader geopolitical concerns, others anticipate a sharp rebound ahead of upcoming earnings, citing strong iPhone demand and a strategic AI roadmap. This creates a sharply divided sentiment on whether the current dip is a buying opportunity or signals further downside.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending due to a significant sell-off in the broader software sector, driven by pervasive investor concerns about AI's disruptive impact on traditional SaaS models. Community sentiment is sharply divided, with some fearing AI will make CRM obsolete while others strongly believe its deep data moat and integrated AI solutions, like Agentforce, position it for long-term growth. This divergence has led many to view the current valuation as an irrational overreaction, presenting a compelling accumulation opportunity.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is at the center of investor discussion, driven by the impending finalization of the TikTok U.S. deal, which some believe could propel its shares significantly higher due to its robust cloud and AI infrastructure backlog. Conversely, a bondholder lawsuit and considerable debt incurred for AI investments are intensifying bearish concerns, leading to a highly divided community outlook on the company's trajectory.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is seeing heightened discussion driven by speculation surrounding Berkshire Hathaway's stake and a recent analyst downgrade, amplifying concerns about competitive pressures and declining sales. Despite these headwinds, many in the community view the current price as a "buying opportunity," citing its strong dividend, defensive sector appeal, and the potential value unlock from its planned company split and new CEO appointment.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is actively discussed amidst significant market volatility, primarily influenced by evolving geopolitical trade concerns impacting the broader tech sector. Despite recent headlines, community discussion highlights immense demand for NVIDIA's AI chips, reportedly sold out through 2027, with many investors viewing current dips as a compelling buying opportunity. This showcases an ongoing tension between macro uncertainties and NVIDIA's foundational role in the rapidly expanding AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The gold–silver ratio has held support near 49 for a fifth consecutive session, Hansen noted.</li><li>Silver’s historic run will begin to test industrial demand, Hansen said in a post on X.</li><li>Silver futures for March 2026 deliveries surged over 6% while gold futures for February 2026 deliveries jumped 3.5%.</li></ul>Precious metals extended their record-breaking rally into Tuesday, with silver surging past $95 an ounce for the first time ever and gold vaulting above $4,700, as investors rushed to safe-haven assets amid increasing geopolitical uncertainties.&nbsp;Spot silver (XAG/USD) prices gained 1.6% to $95.9 an ounce, while spot gold (XAU/USD) rose 1.7% to $4751.4 per ounce. Futures showed stronger momentum as silver futures for March 2026 deliveries surged over 6% while gold futures for February 2026 deliveries jumped 3.5%.<figure class="image"><img src="https://news.stocktwits-cdn.com/Gold_Silver_jpg_5dc6d0027c.webp" alt="Gold Silver .jpg" width="1300" height="880"><figcaption>Spot gold and silver gains in 2026 : Source: TradingView</figcaption></figure>The gold–silver ratio has held support near 49 for a fifth consecutive session, suggesting a possible rotation back into gold, said Ole Hansen, veteran commodities expert and Head of Commodity Strategy for Saxo Bank, in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/Ole_S_Hansen/status/2013623350010990937">post on X</a> on Tuesday.Silver’s historic run will begin to test industrial demand, which typically accounts for nearly 60% of total usage in a year, Hansen added.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/Ole_S_Hansen/status/2013623350010990937"><img src="https://news.stocktwits-cdn.com/Hansen_jpg_117a924f71.webp" alt="Hansen.jpg"></a>Retail sentiment for SPDR Gold Shares ETF (GLD) turned ‘bullish’ from ‘neutral’ a day earlier, while iShares Silver Trust (SLV) remained in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">Markets Watch</h2>European and Asia-Pacific markets largely declined on Tuesday as investors weighed rising geopolitical risks after U.S. President Donald Trump threatened tariffs on goods from eight European countries unless a deal is reached for what he called the “complete and total purchase of Greenland.” Trump outlined 10% tariffs from February 1, rising to 25% by June.U.S. equities fell on Tuesday, with the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) down by 1.4%, the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) fell 1.3%, while the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) declined 1.2%Meanwhile, Japanese government bond yields jumped after Prime Minister Sanae Takaichi called snap elections, pushing 10-year and 30-year yields sharply higher.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-falls-below-100-dma-for-first-time-in-six-months/cmUuY9ZR4OR">TSLA Stock Falls Below 100-DMA For First Time In Over Six Months – Retail Expects Shares To Hit $400 Mark Soon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Gold, Silver Touch Record Highs – Why Commodities Expert Ole Hansen Sees Possible Rotation Back Into Bullion 

Silver surged past $95 an ounce for the first time ever, and gold vaulted above $4,700, as investors rushed to safe-haven assets amid increasing geopolitical uncertainties.

Equity

Tesla, Inc. (NASDAQ: TSLA) releases a financial earnings report on October 23, 2025. (Photo by Mike Campbell/NurPhoto via Getty Images)

TSLA Stock Falls Below 100-DMA For First Time In Over Six Months – Retail Expects Shares To Hit $400 Mark Soon

While the stock tracked broader market weakness on Tuesday, it has underperformed the key indices year to date.

<ul class="summary-bullets"><li>Top Wealth will issue around 15 million Class A ordinary shares and 3 million Class B ordinary shares to the vendors at $7 per share.</li><li>Airentity International specializes in wine authentication, tracking, and distribution across the Asia Pacific region.</li><li>The acquisition will diversify Top Wealth’s premium beverage portfolio alongside its existing premium caviar business.</li></ul>Shares of Top Wealth Group Holding (TWG) surged about 120% after the opening bell on Tuesday, drawing strong investor interest following the company’s agreement to acquire Airentity International, a wine trading group specializing in wine authentication, tracking, and distribution across the Asia Pacific region.Top Wealth will issue approximately 15 million Class A ordinary shares and 3 million Class B ordinary shares to the vendors at an offer price of $7 per share, valuing the target group at $125 million.<a href="https://stocktwits.com/symbol/TWG">TWG</a> was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">Acquisition Rationale</h2>The acquisition will diversify Top Wealth’s premium beverage portfolio alongside its existing premium caviar business. Airentity and its unit, Airentity Technology, have developed and commercialized a wine authentication and tracking system called WATS.The acquisition brings together two businesses with complementary operations and overlapping customer bases. Top Wealth believes the deal will enhance its profitability and expand its asset base.“This acquisition not only broadens our product mix but also deepens our presence in the luxury segment where caviar and fine wine naturally complement each other. We are confident in our unified vision and future growth prospects,” said CEO Kim Kwan Kings, Wong.Through its Hong Kong subsidiary, Top Wealth Group supplies premium sturgeon caviar under both customer private labels and its own “Imperial Cristal Caviar” brand. Recently, the company said it expects a strong profit rebound for the year ending Dec. 31, 2025, projecting a net profit of at least $4 million, compared to a loss of $2 million a year earlier.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail chatter picked up significantly on Stocktwits, with message volumes increasing to ‘extremely high’ from ‘low’, while sentiment flipped to ‘extremely bullish’ from ‘bearish’ a day earlier.<img src="https://news.stocktwits-cdn.com/TWG_jpg_1a02f60be0.webp" alt="TWG.jpg">Many users eye $20 as the stock’s price target.<stembedurl>https://stocktwits.com/89gt/message/642276980</stembedurl><stembedurl>https://stocktwits.com/updog1/message/642275499</stembedurl>The stock has shed about 65% of its value over the past year.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-nvax-stock-rising-premarket-pfizer-matrix-m-deal/cmUumrjR4aq">Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

This Nanocap Stock More Than Doubled Today – What’s Driving The Rally?

Top Wealth Group Holding signed an agreement to acquire Airentity International, a wine trading group, for around $125 million.

<ul class="summary-bullets"><li>The deal provides Novavax with an upfront payment of $30 million, along with the opportunity to earn up to $500 million in additional development and sales milestones.</li><li>Matrix-M adjuvant is a proprietary vaccine ingredient, used in several marketed vaccines to improve effectiveness and help the immune system better recognize and remember disease targets.</li><li>Novavax is eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M.</li></ul>Novavax, Inc. (NVAX) shares climbed 6% higher in pre-market trading on Tuesday after the company signed a licensing agreement with Pfizer, granting the pharmaceutical giant non-exclusive rights to use Novavax’s Matrix-M adjuvant in up to two disease areas.Matrix-M adjuvant is a proprietary vaccine ingredient that improves the body’s immune response. It is made from naturally derived compounds and is used in several marketed vaccines to improve effectiveness and help the immune system better recognize and remember disease targets, according to Novavax.<h2 class="st-heading-2">What Is The Novovax-Pfizer Deal?</h2>The deal provides Novavax with an upfront payment of $30 million, along with the opportunity to earn up to $500 million in additional development and sales milestones. Novavax is also eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M.Under the agreement, Pfizer will take full responsibility for the development and commercialization of its products, while Novavax will supply the Matrix-M adjuvant. The partnership strengthens Novavax’s long-term revenue potential.This comes after Novavax completed the transfer of U.S. and European marketing authorizations for its COVID-19 vaccine, Nuvaxovid, to Sanofi in November. The move resulted in a second $25 million milestone payment to Novavax, following the completion of the European Union marketing authorization transfer in October 2025.Novavax is expected to receive additional milestone payments and royalties tied to Nuvaxovid, Sanofi-developed combination products, and new vaccines that use Novavax’s Matrix-M adjuvant. Novavax also has long-standing partnerships with Japan’s Takeda and the Serum Institute of India.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/NVAX">NVAX</a> on Stocktwits remained in the ‘extremely bullish’ zone, amid ‘extremely high’ message volumes. NVAX was also among the top three trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/NVAX_jpg_1f4183eedd.webp" alt="NVAX.jpg">One bullish user said that the stock is undervalued.<stembedurl>https://stocktwits.com/ejaXstoXX/message/642272237</stembedurl>Another user was bullish about Matrix-M’s market potential.<stembedurl>https://stocktwits.com/P38FTD/message/642271830</stembedurl>The stock has declined around 6% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-ivf-stock-soaring-premarket/cmUum0oR4ap">INVO Fertility’s 350% Spike Puts Microcap IVF Stocks Back On Retail Radar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It?

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.

NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology

<ul class="summary-bullets"><li>Last month, INVO Fertility signed a definitive agreement to acquire Family Beginnings, a fertility clinic.</li><li>INVO Fertility also announced a private placement worth $4 million last month.</li><li>Terah Krigsvold recently took over as IVF’s chief financial officer, replacing Andrea Goren.</li></ul>INVO Fertility, Inc. (IVF) shares drew significant retail interest on Tuesday, with the stock soaring 350% in premarket trading.Retail watchers for <a href="https://stocktwits.com/symbol/INVO">IVF stock</a> increased a whopping 726% over the last 24 hours and 3,700% over seven days, according to Stocktwits data. Retail sentiment on Stocktwits was ‘extremely bullish’ over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/INVO_jpg_f619340f95.webp" alt="INVO.jpg">A few users speculated on U.S. President Donald Trump cutting costs for fertility treatments.<stembedurl>https://stocktwits.com/DekmarTrades/message/642263565</stembedurl>While others saw a classic pump-and-dump scheme.<stembedurl>https://stocktwits.com/Bonanza2252003/message/642265944</stembedurl>The speculation stems from an October 2025 report on Trump and Merck’s agreeing to reduce the cost of drugs used in in vitro fertilization. Merck’s U.S. unit, EMD Serono, will sell key fertility treatments directly to patients, offering up to an 84% discount when the drugs are used together.<h2 class="st-heading-2">Why Has Retail Been Tracking IVF?</h2>Last month, INVO Fertility signed a definitive agreement to acquire Family Beginnings, P.C., a fertility clinic serving Indiana and the broader Midwest. The deal allows INVO to strategize to expand its network of fertility care centers across the United States.INVO will acquire the non-clinical assets for $750,000, consisting of $350,000 in cash at closing, net of a $150,000 holdback, and $400,000 in Series D non-voting convertible preferred stock. Family Beginnings generated approximately $1.2 million in revenue and $0.2 million in net income over the past year.Prior to that, INVO Fertility announced a private placement with a single institutional investor to sell 2.37 million shares, or pre-funded warrants, along with warrants for up to 4.73 million additional shares, at an effective price of $1.69 per share. The offering generated around $4 million in gross proceeds.Recently, Terah Krigsvold, who has served as INVO’s controller since December 2020, was appointed the Company’s CFO, replacing Andrea Goren. INVO Fertility also implemented a one-for-eight reverse stock split on Nov. 28, 2025.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-ibrx-stock-surging-premarket-fda-anktiva-resubmission/cmUujB3R4aL">IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INVO Fertility’s 350% Spike Puts Microcap IVF Stocks Back On Retail Radar

Retail watchers for IVF stock increased a whopping 726% over the last 24 hours and 3,700% over seven days, according to Stocktwits data.

A Little-Known Fertility Stock Soared 350% — Here’s What Traders Are Watching

<ul class="summary-bullets"><li>ANKTIVA is an Interleukin-15 (IL-15) receptor agonist that helps develop and activate key cells that work to destroy cancer cells.</li><li>The company presented an overview of the clinical status of its papillary disease program, including more than five years of follow-up data.</li><li>The data demonstrated strong bladder preservation outcomes.</li></ul>ImmunityBio (IBRX) shares rose 6% in pre-market trading on Tuesday after the United States Food and Drug Administration (FDA) outlined a pathway for resubmitting its supplemental biologics license application (sBLA) for ANKTIVA in Bacillus Calmette Guérin (BCG)-unresponsive papillary bladder cancer, without requesting new trials.&nbsp;The company said it recently met with the FDA for a Type B end-of-phase meeting to review data spanning over five years.<h2 class="st-heading-2">The FDA Meeting</h2>During the meeting, ImmunityBio presented more than five years of follow-up data supporting the papillary disease indication. Long-term results, published in The Journal of Urology, showed bladder cancer–specific survival of around 96% at three years, with median survival not yet reached.The data also demonstrated strong bladder preservation outcomes, with cystectomy avoidance rates of 92% at one year and 82% at three years, alongside a safety profile consistent with ANKTIVA’s currently approved use in carcinoma in situ (CIS).Based on these discussions, the FDA recommended that ImmunityBio submit additional information for further evaluation to potentially support a resubmission of the sBLA initially filed in 2025. The Agency did not request any new clinical trials.“We have completed the assembly and analysis of the requested additional information and will submit it within the next 30 days for the Agency’s review,” said Richard Adcock, President and CEO of ImmunityBio.ANKTIVA is an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells. It is already commercially available in the U.S. for NMIBC CIS, with or without papillary tumors, and has received approvals in the U.K. and Saudi Arabia, as well as conditional approval in the European Union.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes. IBRX was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_704152379c.webp" alt="IBRX.jpg">One user laid out the potential triggers for the stock.<stembedurl>https://stocktwits.com/end2war/message/642249657</stembedurl>Over the past year, the stock has gained 85,% and year-to-date, it has added more than 173%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-rapt-stock-surge-63-in-pre-market-today/cmUuK0vR4aO">Why Did RAPT Stock Surge 63% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing

The company said it recently held end-of-phase talks with the United States Food and Drug Administration on its ANKTIVA application for treatment-resistant papillary bladder cancer.

This FDA Signal Is Powering IBRX Stock's Pre-Market Jump

<ul class="summary-bullets"><li>GSK signed an agreement to acquire RAPT Therapeutics for around $2.2 billion.</li><li>The deal centers on an experimental allergy drug that could reshape treatment frequency and expand patient access.</li><li>The transaction is expected to close in the first quarter of 2026.</li></ul>Shares of RAPT Therapeutics (RAPT) surged 63% in pre-market trading on Tuesday after GSK Plc announced a definitive agreement to acquire the California-based clinical-stage biopharmaceutical company for around $2.2 billion.Under the agreement, GSK will acquire RAPT for $58.00 per share in cash, a 65.2% premium over Friday’s closing price of $35.1. GSK’s upfront investment is estimated at about $1.9 billion. The transaction is expected to close in the first quarter of 2026.If the level holds after the opening bell, RAPT shares will climb to their highest levels since May 2024.<h2 class="st-heading-2">What Is The Deal About?</h2>The agreement centers on Ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody currently in phase IIb development for the prevention of food allergy reactions. IgE remains the only approved systemic therapy proven to protect patients from severe allergic and inflammatory immune responses. The acquisition will add to GSK’s respiratory, immunology &amp; inflammation pipeline.The deal grants GSK global rights to Ozureprubart, excluding mainland China, Macau, Taiwan, and Hong Kong. GSK will also assume responsibility for success-based milestone and royalty payments owed to RAPT’s partner, Shanghai Jeyou Pharmaceutical.Existing anti-IgE therapies typically require injections every two to four weeks, but Ozureprubart has the potential to reduce dosing frequency to once every 12 weeks. It may also expand treatment access to roughly 25% of patients who are currently ineligible for existing therapies.The Food and Drug Administration (FDA) had cleared the company’s investigational new drug (IND) application to advance Ozureprubart into a Phase IIb food allergy trial in September, and in October, RAPT launched the prestIgE study, a randomized, double-blind, placebo-controlled trial. Phase IIb data from the prestIgE trial are expected in 2027, with phase III studies planned in both adult and pediatric populations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/RAPT">RAPT</a> turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid ‘high’ message volumes, while sentiment for GSK’s U.S.-listed shares remained in the ‘neutral’ zone.<img src="https://news.stocktwits-cdn.com/RAPT_jpg_5e9736f28c.webp" alt="RAPT.jpg">Over the past year, RAPT stock has gained more than 250%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-nvda-stock-down-in-premarket-today/cmUuhayR4aB">Why Is NVDA Stock Down 3% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did RAPT Stock Surge 63% In Pre-Market Today?

GSK will acquire RAPT for $58.00 per share in cash, a 65.2% premium over Friday’s closing price of $35.1.

RAPT Stock Soars On GSK Takeover Deal Valuing Company At $2.2 Billion

<ul class="summary-bullets"><li>Oppenheimer downgraded Mosaic to ‘Perform’ from ‘Outperform’.</li><li>Tight sulfur market conditions are expected to persist into the first half of 2026, continuing to weigh on Mosaic’s outlook, the brokerage firm added.</li><li>Tight credit and increased competition due to an influx of lower-grade phosphate imports from China weighed on demand and margins in Brazil.</li></ul>Mosaic Company (MOS) shares were trading down 4.5% on Friday after the firm said that fertilizer market conditions remained challenging in the fourth quarter (Q4) of 2025, as weaker-than-usual seasonal demand weighed on results.In response, Oppenheimer downgraded Mosaic to ‘Perform’ from ‘Outperform’ and removed the firm’s previous $35 price target following the company’s “weak” preliminary Q4 results.Oppenheimer expects Mosaic to continue making gradual progress on operating rates, but noted there is no clear catalyst to lift fertilizer demand in the current crop year. Tight sulfur market conditions are also expected to persist into the first half of 2026, continuing to weigh on the outlook.Despite the intraday drop, retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours.<h2 class="st-heading-2">Q4 Preliminary Update</h2>In North America, fertilizer demand dropped sharply as growers remained under economic pressure and an early winter shortened the fall application season. Phosphates were hit hardest due to lower affordability than potash, with shipments estimated to be down about 20% from a year ago.The weak environment weighed on Mosaic’s results, with Q4 phosphate sales of about 1.3 million tonnes and potash sales near 2.2 million tonnes. In response, the company adjusted its phosphate production and shifted volumes to markets showing stronger demand, keeping overall output in line with the prior quarter, though lower sales and rising inventories pressured cash flow.Conditions in Brazil also worsened, as tighter credit and increased competition, due to an influx of lower-grade phosphate imports from China, weighed on demand and margins. As a result, Mosaic Fertilizantes’ sales fell short of expectations, even as full-year volumes were roughly flat.Looking ahead, Mosaic sees a more favorable setup in 2026, supported by nutrient replenishment needs, government support programs, tightening phosphate markets, and reduced Chinese exports, all of which could help lift demand and prices over time, it said.The company is expected to post its Q4 2025 results on February 24.Over the past year, <a href="https://stocktwits.com/symbol/MOS">MOS stock</a> has declined nearly 2%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-abus-stock-fall-today/cmUlzXeR4BY">ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Mosaic Company logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MOS Stock Sees Red As Cheaper Chinese Imports Weigh On Q4 Operations

Mosaic Company said that fertilizer market conditions remained challenging in the fourth quarter, as weaker-than-usual seasonal demand weighed on results.

<ul class="summary-bullets"><li>The verbal ruling was delivered on January 15, without written reasons, the company said.</li><li>The company said it disagrees with the outcome and plans to seek a review by the Enlarged Board of Appeal once the written ruling is issued.</li><li>The company does not expect the ruling to impact outcomes of its patent infringement cases against Moderna.</li></ul>Arbutus Biopharma Corp. (ABUS) stock crashed more than 18% on Friday after the European Patent Office (EPO) revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.This marked the <a href="https://stocktwits.com/symbol/ABUS">ABUS stock’s</a> biggest intraday decline since July 2020.The verbal ruling was delivered on January 15 without written reasons, Arbutus said. The EPO ruling reverses two earlier decisions that had upheld an amended version of the patent EP 2279254. According to Google Patents, it covers “Novel lipid formulations for nucleic acid delivery.”The company said it disagrees with the outcome and plans to seek a review by the Enlarged Board of Appeal once the written ruling is issued. Arbutus acknowledged that the decision could affect certain European legal actions against Moderna, including a case in Switzerland and a proceeding before the Unified Patent Court in which the patent is being asserted.<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> (MRNA) jumped 7%, while <a href="https://stocktwits.com/symbol/MRK">Merck</a> (MRK) traded 2% lower.<h2 class="st-heading-2">Impact Outside Europe</h2>Arbutus stressed that the revocation was based on the EPO’s “added matter” standard, which does not apply in other jurisdictions.As a result, the company does not expect the ruling to impact the timing or potential outcomes of its patent infringement cases against Moderna in the United States, Japan, or Canada, a separate Unified Patent Court case not involving the patent, or its ongoing litigation against Pfizer and BioNTech in the U.S.<h2 class="st-heading-2">Retail Reaction</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/ABUS_jpg_f665738876.webp" alt="ABUS.jpg">One user sees the drop as an opportunity to take up fresh positions.<stembedurl>https://stocktwits.com/LS172/message/642060814</stembedurl>One user said it’s all noise and nothing has changed ‘other than the bad headline’.<stembedurl>https://stocktwits.com/EdDwg/message/642040053</stembedurl>The stock has gained around 20% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-jfbr-stock-surge-today/cmUlvsnR4B0">Why This Penny Stock Is On Track To Gain For First Time In 10 Sessions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Plug Power said it was impacted by the speed and development of hydrogen economy.

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?

The European Patent Office revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.

<ul class="summary-bullets"><li>The agreement allows up to six months of exclusivity for approved customers.</li><li>The partnership targets use cases such as border security, counter-terrorism, and critical infrastructure protection.</li><li>Approved customers include Canada’s Department of National Defence and Royal Canadian Mounted Police, as well as Mexican agencies such as the Secretaría de la Defensa Nacional and the Guardia Nacional.</li></ul>Jeffs’ Brands (JFBR) sparked excitement among retail investors as the stock soared over 230% after the opening bell on Friday, driven by news of a partnership with an Israeli defense company.If the rally holds, it would mark the first gain for <a href="https://stocktwits.com/symbol/JFBR">JFBR stock</a> in 10 sessions.<h2 class="st-heading-2">Details Of The Deal</h2>Jeffs’ Brands’ subsidiary, KeepZone AI, signed a distribution agreement with STI, an Israeli homeland security technologies firm. Under the deal, KeepZone will distribute STI’s products in Canada and Mexico, marking a crucial step in Jeffs’ Brands’ expansion plans beyond e-commerce.The agreement allows up to six months of exclusivity for approved customers, allowing KeepZone to work directly with key government and security agencies without competition from other distributors.Approved customers include Canada’s Department of National Defence and Royal Canadian Mounted Police, as well as Mexican agencies such as the Secretaría de la Defensa Nacional and the Guardia Nacional.The partnership targets use cases such as border security, counter-terrorism, and critical infrastructure protection, and features technologies such as under-vehicle inspection systems and explosives detection devices.The agreement builds on KeepZone’s recent partnerships with Scanary, Zorronet, and RT LTA Systems to offer AI-enabled, multi-layered security ecosystems.“We believe this Agreement expands our ability to deliver comprehensive, end-to-end solutions to government and enterprise clients in North America. STI’s innovative detection systems align perfectly with our mission to support proactive threat mitigation, enhancing safety in critical areas like borders and public infrastructure,” said KeepZone CEO Alon Dayan.<h2 class="st-heading-2">How Did Retail React?</h2>The deal generated significant buzz on Stocktwits with retail sentiment flipping to ‘extremely bullish’ from ‘bearish’ a day ago. Message volumes tracking the stock on the platform were ‘extremely high’.<img src="https://news.stocktwits-cdn.com/JFBR_jpg_24c47fd98d.webp" alt="JFBR.jpg">One user saw $1.55 as a key resistance level. The stock is currently trading at $1.26.<stembedurl>https://stocktwits.com/TheRealJohnWayne/message/642030381</stembedurl>Another user saw potential for 10x gains.<stembedurl>https://stocktwits.com/WadehN21/message/642036302</stembedurl>Over the past year, the stock has been under intense selling pressure, declining nearly 97%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-nukk-stock-rising-pre-market-today/cmUlMF2R4BX">Why Is NUKK Stock Rising Pre-Market Today?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Jeffs' Brands logo is displayed on the screen of an iPad. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why This Penny Stock Is On Track To Gain For First Time In 10 Sessions

Jeffs’ Brands, via its unit, signed a distribution agreement with an Israeli homeland security technologies firm to distribute products in Canada and Mexico.